AxoGen (AXGN) is Reiterated by Wedbush to Outperform, Raises Price Target to $ 10

AxoGen (AXGN) was Reiterated by Wedbush to “Outperform” according to the research note released today. The brokerage firm has raised the Price Target to $ 10 from a previous price target of $9 . Wedbush advised their investors in a research report released on Aug 4, 2016.

AxoGen opened for trading at $6.6 and hit $6.76 on the upside on Tusday, eventually ending the session at $6.69, with a gain of 0.75% or 0.05 points. The heightened volatility saw the trading volume jump to 2,27,077 shares. Company has a market cap of $201 M.

In a different news, on Nov 12, 2015, Mark Stephen Gold (director) sold 6,013 shares at $5.70 per share price. According to the SEC, on Jun 5, 2015, Joseph M Mandato (director) purchased 6,500 shares at $3.10 per share price. On Jun 3, 2015, Lee Robert Jr Johnston (Chief Finacial Officer) purchased 5,000 shares at $3.07 per share price, according to the Form-4 filing with the securities and exchange commission.


Leave a Reply

AxoGen - Is it time to Sell?

Top Brokerage Firms are advising their investors on AxoGen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.